FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells.
about
FES kinases are required for oncogenic FLT3 signalingDownstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implicationsMolecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted TherapyAn overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatmentMutant FLT3 signaling contributes to a block in myeloid differentiationThe FLT3 inhibitor quizartinib inhibits ABCG2 at pharmacologically relevant concentrations, with implications for both chemosensitization and adverse drug interactionsCell-based selection of internalizing fully human antagonistic antibodies directed against FLT3 for suppression of leukemia cell growth.Ral is both necessary and sufficient for the inhibition of myeloid differentiation mediated by RasSelective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.The Cytokine Flt3-Ligand in Normal and Malignant HematopoiesisPatterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemiaPhase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.The Biology and Targeting of FLT3 in Pediatric Leukemia.Flt3 does not play a critical role in murine myeloid leukemias induced by MLL fusion genes.Further activation of FLT3 mutants by FLT3 ligandABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia.Meis1 programs transcription of FLT3 and cancer stem cell character, using a mechanism that requires interaction with Pbx and a novel function of the Meis1 C-terminus.Restoration of CCAAT enhancer binding protein α P42 induces myeloid differentiation and overcomes all-trans retinoic acid resistance in human acute promyelocytic leukemia NB4-R1 cells.Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target.Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia.Aberrant cytokine signaling in leukemia.High-affinity neurotrophin receptors and ligands promote leukemogenesis.Survivin mediates aberrant hematopoietic progenitor cell proliferation and acute leukemia in mice induced by internal tandem duplication of Flt3.Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors.ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside.Mechanisms of resistance to FLT3 inhibitors.Novel targeted drug therapies for the treatment of childhood acute leukemiaA noncanonical Flt3ITD/NF-κB signaling pathway represses DAPK1 in acute myeloid leukemia.FLT3 inhibitors: clinical potential in acute myeloid leukemia.FMS-related tyrosine kinase 3 ligand (Flt3L)/CD135 axis in rheumatoid arthritisTargeting FLT3 to treat leukemia.Microfluidic platforms for the investigation of intercellular signalling mechanisms.T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3-ITD mutated acute myeloid leukemia.Induced Apoptosis Investigation in Wild-type and FLT3-ITD Acute Myeloid Leukemia Cells by Nanochannel Electroporation and Single-cell qRT-PCR.Development and Characterization of FLT3-Specific Curcumin-Loaded Polymeric Micelles as a Drug Delivery System for Treating FLT3-Overexpressing Leukemic Cells.Isolation of human mAbs that directly modulate FMS-related tyrosine kinase 3 signaling.Autocrine insulin-like growth factor-I signaling promotes growth and survival of human acute myeloid leukemia cells via the phosphoinositide 3-kinase/Akt pathway.Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways.Constitutively activated FLT3 phosphorylates BAD partially through pim-1.Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors.
P2860
Q24297863-614DA590-98FC-43D8-98E4-9EC32996B338Q24617091-E8EEC7E0-D564-4A80-AC9B-336FE78330B7Q26749870-F858AA5D-4D24-4512-9585-589FBF99367AQ27027207-62AA7582-2547-40B1-B41A-003D35869080Q28279890-55B2A827-63C9-4094-BD1D-B7370E289054Q28535342-FF5EA06C-30AE-4B19-8E36-264EBB583421Q33216322-E3C2D4F5-B67E-414B-B296-1CE85172A9FFQ33241589-D31AA150-CA5F-436E-B516-94A571048CAEQ33442949-8881621A-703D-4B18-A1C6-89EA0C36A29EQ33838356-E509B9EC-322B-48EB-A298-4C988565C9BDQ33913329-B3D86AA1-F74B-4FDA-BE17-A16ED0E50638Q34095013-800D2C92-86E6-49C5-BAE5-DDA95F891BA0Q34229555-794D8705-B97E-4C29-9BF0-0C1162EE79C0Q34973744-E901DD2D-2417-45E3-AC4F-E9AB431BD46BQ35163307-13D51AB5-C577-46B8-8FEC-8831E289339AQ35751114-F501CB1E-AFE1-4D9E-891C-9D255C693862Q35847824-E2147300-2E6D-4895-89BC-69CD841ADC43Q36140549-43C3295A-F2F8-4EAB-9047-0C364E6AB3BEQ36682854-82C3430F-C506-4DC2-966B-27B28AABC46BQ36758390-06658CA8-7B6D-4BC8-9653-5822C5712C4BQ36970192-06BA4EB0-01A0-4A86-8638-FEC57D1BD4D3Q37116938-3895D242-B4B4-473F-ACE9-3520222AF152Q37271051-27AE31ED-DE41-408C-81C2-6ADDEAC64036Q37294768-0BA7A81C-CCFF-49D2-915A-5FAA201C8A5BQ37312735-03CE5AA0-2C8F-4E63-B6E1-54CA7E20C5ECQ37375423-A587A1FE-7CCA-4050-A06D-544D4F06B473Q37477482-C872D023-9C36-4846-8CDE-E5DF4A776F38Q37569994-B0663098-FE1F-4F85-B316-12DA396F0CCCQ37638749-5BDDF92E-F30E-4AA8-AD15-D5830A162EFFQ37690021-25B22100-26B7-4514-8131-31F0ABC0129AQ38251339-B19BB15F-F5BF-404A-93B3-2986E94731D6Q38252625-565C1BBC-3644-4284-8A6C-95F9D20C8E36Q38261327-75067907-A1DB-4672-9D3D-FB55162F93CFQ38801957-0FD73F1B-BC34-46CF-85BE-1D99D5DA8C00Q38810295-A7B544A8-6523-4972-9D55-069E6B3C9FE6Q39448700-181BC759-ECF6-4652-94F9-92AEB3987D0BQ40117414-95FCFDC0-F8AB-4714-814A-BA616141C4F6Q40218888-225D295B-F5C4-4E3F-BF94-E2A1B39084C1Q40251345-9F3F613F-8857-4ECC-9C2A-B33A3C755CC4Q40859498-D0923A3D-A105-4457-AEC4-976807A12BCD
P2860
FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells.
@en
type
label
FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells.
@en
prefLabel
FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells.
@en
P2093
P1433
P1476
FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells.
@en
P2093
Brenda R Baldwin
Dale Ludwig
Dan Hicklin
Donald Small
Larry Witte
Mark Levis
Miloslav Beran
Norbert C Gorin
Obdulio Piloto
Patrick Brown
P304
P356
10.1182/BLOOD-2003-06-1969
P407
P577
2003-09-11T00:00:00Z